A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
UMC Utrecht
Pfizer
A2 Biotherapeutics Inc.
H. Lee Moffitt Cancer Center and Research Institute
University of Colorado, Denver
City of Hope Medical Center
University of Nebraska
Seagen Inc.
Novartis
Var2 Pharmaceuticals